Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…

Immix Biopharma, Inc.
Next earnings Aug 6, 2026 · consensus $-0.19 EPS
Conservative balance sheet (liabilities/equity 0.12x).
Immix Biopharma, Inc. shows limited reported revenue, and -31.4% ROE.
Sources: SEC EDGAR (CIK 0001873835, latest 10-Q filed 2026-05-07) · EODHD · as of 6/22/2026, 12:29:44 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$1.35M | -$8.22M | -$16.1M | -$22.7M | -$30.0M |
| Net income | -$24.4M | -$8.23M | -$15.4M | -$21.6M | -$29.4M |
| Diluted EPS | — | -$0.59 | -$0.89 | -$0.76 | -$0.89 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1483 tracked peers · median
| 2026-05-22 | Adams Helen C. Director | Award | 6.25K | |
| 2026-05-22 | Ng Carey Director | Award | 6.25K | |
| 2026-05-22 | Marquet Magda Director | Award | 6.25K | |
| 2026-05-22 | CHANG NANCY T Director | Award | 6.25K | |
| 2026-05-22 | Chudnovsky Yekaterina Director | Award | 6.25K | |
| 2026-05-22 | Hsu Jason Director | Award | 6.25K |
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.